CYCC Cyclacel Pharmaceuticals Inc
16,217
$2.29
$0.05
(2.14%)
| Watchers | 16,217 |
| 52-Wk Low | $1.30 |
| 52-Wk High | $13.20 |
| Market Cap | $3.35M |
| Volume | 34,988.00 |
| 52-Wk High | $13.20 |
| 52-Wk Low | $1.30 |
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib's Potential as a Precision Medicine for CancerGlobe Newswire • about 2 months ago
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J...
Share to Feed
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC Get Free Report) saw a large drop in short interest in March. As of March 15th, there was short interest totalling 26,600 shares, a drop of 35.9...
StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC Free Report) from a sell rating to a hold rating in a report issued on Tuesday morning.
A number of other brokerages...
StockNews.com cut shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC Free Report) from a hold rating to a sell rating in a research report report published on Monday morning. Other analysts have...
On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation Oral Plogosertib Preclinical Data Support Precision...
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
StockNews.com upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC Free Report) from a sell rating to a hold rating in a research note released on Thursday morning. Several other...
Data support ongoing development program of novel CDK2/9 inhibitor fadraciclib in patients with solid tumors and lymphomaBERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
BERKELEY HEIGHTS, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...